Announcement PDF ASX RELEASE 13th December 2024 Notice under Section 708A(5)(e) of the Corporations Act 2001 (Cth) Paradigm Biopharmaceuticals Limited (the "Company") refers to the issue of 40,000,000 fully paid ordinary shares in the Company on 13 December 2024 (the "Securities"), which were issued without disclosure to investors under Part 6D.2 of the Corporations Act 2001 (Cth) (the "Act"). The Company advises pursuant to section 708A(5)(e) of the Act that: 1. The Securities were issued without disclosure to investors under Part 6D.2 of the Act. 2. This notice is being given under Section 708A(5)(e) of the Act. 3. As at the date of this notice, the Company has complied with: 4. a. the provisions of Chapter 2M of the Act as they apply to the Company; and b. section 674 and section 674A of the Act. As at the date of this notice, there is no information that is “excluded information” within the meaning of section 708A(7) of the Act that is required to be disclosed by the Company in accordance with section 708A(8) of the Act. This notice has been authorised for release to the ASX by the Board of Directors. -EndsAbout Paradigm Biopharmaceuticals Ltd. Paradigm Biopharmaceuticals Ltd. (ASX:PAR) is a late-stage drug development company driven by a purpose to improve patients’ health and quality of life by discovering, developing, and delivering pharmaceutical therapies. Paradigm’s current focus is developing injectable (subcutaneous) pentosan polysulfate sodium (iPPS) for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of iPPS, such as in osteoarthritis (phase 3) and mucopolysaccharidosis (phase 2). To learn more please visit: https://paradigmbiopharma.com FOR FURTHER INFORMATION PLEASE CONTACT: Simon White Director of Investor Relations Tel: +61 404 216 467 Paradigm Biopharmaceuticals Ltd ABN: 94 169 346 963 Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA Email: investorrelations@paradigmbiopharma.com